Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis and as DIAPRIDE by Micro Labs Ltd. Glimepiride is the first third-generation sulfonylurea, and is very potent.
It is sometimes classified as third-generation,[1] and sometimes classified as second-generation.[2]
It is sometimes classified as third-generation,[1] and sometimes classified as second-generation.[2]
GI disturbance, rarely thrombopenia , leucopenia, haemolytic anaemia, occasionally allergic. In the initial weeks of treatment, the risk of hypoglycemia may be increased.
No comments:
Post a Comment